Key Insights

Highlights

Success Rate

81% trial completion

Published Results

20 trials with published results (26%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

9.0%

7 terminated out of 78 trials

Success Rate

80.6%

-6.0% vs benchmark

Late-Stage Pipeline

8%

6 trials in Phase 3/4

Results Transparency

69%

20 of 29 completed with results

Key Signals

20 with results81% success

Data Visualizations

Phase Distribution

65Total
Not Applicable (9)
Early P 1 (1)
P 1 (21)
P 2 (28)
P 3 (3)
P 4 (3)

Trial Status

Completed29
Recruiting20
Unknown11
Active Not Recruiting9
Terminated7
Withdrawn1

Trial Success Rate

80.6%

Benchmark: 86.5%

Based on 29 completed trials

Clinical Trials (78)

Showing 20 of 20 trials
NCT03779854Phase 2Recruiting

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

NCT02506933Phase 2Active Not Recruiting

Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant

NCT07586618Phase 1RecruitingPrimary

First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.

NCT01574274Phase 2Active Not Recruiting

SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma

NCT07020533Phase 1Recruiting

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

NCT06533748Phase 2Recruiting

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

NCT06364423Phase 1Recruiting

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

NCT06289673Phase 4Recruiting

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

NCT05602194Phase 3Active Not Recruiting

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

NCT03810196Not ApplicableRecruiting

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

NCT03932903Not ApplicableRecruiting

Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia

NCT03314974Phase 2Recruiting

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

NCT07634653Not ApplicableNot Yet Recruiting

Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL)

NCT05428176Not ApplicableActive Not Recruiting

A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer Survivors

NCT02220985Phase 2Completed

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

NCT04195633Phase 2Recruiting

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

NCT01962636Not ApplicableTerminated

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

NCT01790152Recruiting

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

NCT05794880Not ApplicableRecruiting

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

NCT06514794Phase 2Recruiting

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Scroll to load more

Research Network

Activity Timeline